The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease

Abstract

Thrombus formation underpins the development of cardiovascular diseases, including acute coronary syndromes and ischaemic stroke. A number of wellcharacterised cardiovascular risk factors which contribute to the development of the majority of cardiovascular events have been identified, including dyslipidaemia, hypertension and diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a 3- to 5-fold increased risk for development of cardiovascular disease (CVD). They may have a cluster of haemostatic abnormalities, including elevated levels of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, which contribute to acute thrombotic events. It is clear that additional unidentified risk factors contribute to the pathogenesis of cardiovascular events, and so the search for novel biomarkers and effectors, particularly in individuals with T2DM, remains a major challenge of cardiovascular medicine.

Plasma and cellular proteins which contribute to thrombus formation have the potential to confer a prothrombotic state and represent a link between genotype, environment and disease phenotype. The comprehensive analysis of these proteins is now increasingly facilitated through the continued development of proteomic technologies which provide multifaceted approaches to the identification of novel biomarkers and/or effectors of thrombus formation and on which future anticoagulant and thrombolytic therapies may be based.

This review provides an overview of current proteomic technologies. It focuses on the recent studies in which these technologies have been applied in the search for novel proteins that may confer increased risk of acute cardiovascular diseases and therefore that may influence disease progression and therapy.

Keywords

coronary syndrome proteomics thrombosis

References

1. Powell DW Merchant ML , Link JA. Discovery of regulatory molecular events and biomarkers using 2D capillary chromatography and mass spectrometry. Expert Rev Proteomics 2006;3:63–74.

2. Scott EM Carter AM , Findlay BJ. The application of proteomics to diabetes. Diabetes Vasc Dis Res 2005;2:54–60, doi: 10.3132/dvdr.2005.009.

3. Aebersold R. A mass spectrometric journey into protein and proteome research. J Am Soc Mass Spectrom 2003;14:685–95.

4. Drake TA Ping P Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Proteomics approaches to the systems biology of cardiovascular diseases. J Lipid Res 2007;48:1–8.

5. Meilhac O Delbosc S , Michel BJ. Cardiovascular biomarker discovery by SELDI-TOF mass spectrometry. Methods Mol Biol 2007;357:331–41.

6. Chang IF. Mass spectrometry-based proteomic analysis of the epitopetag affinity purified protein complexes in eukaryotes. Proteomics 2006;6:6158–66.

7. Andre M Le Caer JP , Greco C et al. Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 2006;6:1437–49.

8. Corthals GL Aebersold R , Goodlett RD. Identification of phosphorylation sites using microimmobilized metal affinity chromatography. Methods Enzymol 2005;405:66–81.

9. Anderson NL Anderson GN. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–67.

10.

10. Zhang Q Tang N , Brock JW et al. Enrichment and analysis of nonenzymatically glycated peptides: boronate affinity chromatography coupled with electron-transfer dissociation mass spectrometry. J Proteome Res 2007;6:2323–30.

11.

11. Liu T Qian WJ , Mottaz HM et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006;5:2167–74.

12.

12. Song Y Hao Y , Sun A et al. Sample preparation project for the subcellular proteome of mouse liver. Proteomics 2006;6:5269–77.

13.

13. Gorg A Weiss W , Dunn JM. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665–85.

14.

14. Dowsey AW Dunn MJ , Yang ZG. The role of bioinformatics in twodimensional gel electrophoresis. Proteomics 2003;3:1567–96.

15.

15. Tam SW Pirro J , Hinerfeld D. Depletion and fractionation technologies in plasma proteomic analysis. Expert Rev Proteomics 2004;1:411–20.

16.

16. Ramstrom M Bergquist J Miniaturized proteomics and peptidomics using capillary liquid separation and high resolution mass spectrometry. FEBS Lett 2004;567:92–5.

17.

17. Zhang L Xie J , Wang X et al. Proteomic analysis of mouse liver plasma membrane: use of differential extraction to enrich hydrophobic membrane proteins. Proteomics 2005;5:4510–24.

18.

18. Kislinger T Gramolini AO , MacLennan DH , Emili A. Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J Am Soc Mass Spectrom 2005;16:1207–20.

19.

19. Aebersold R. Quantitative proteome analysis: methods and applications. J Infect Dis 2003;187(suppl 2):S315–S320.

20.

20. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005;563:23–60.

21.

21. Mateos-Caceres PJ , Garcia-Mendez A , Lopez Farre A et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004;44:1578–83.

22.

22. Marshall J Kupchak P , Zhu W et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361–72.

23.

23. Donahue MP Rose K , Hochstrasser D et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J 2006;152:478–85.

24.

24. Omenn GS States DJ , Adamski M et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226–45.

25.

25. Berhane BT Zong C , Liem DA et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005;5:3520–30.

26.

26. Howes J-M , Keen JN , Findlay JBC , Grant PJ , Carter AM. Characterizing the plasma clot proteome. J Thromb Haemost 2005;3: Abstract 2079.

27.

27. Garcia A Watson SP , Dwek RA , Zitzmann N. Applying proteomics technology to platelet research. Mass Spectrom Rev 2005;24:918–30.

28.

28. Garcia A Prabhakar S , Hughan S et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 2004;103:2088–95.

29.

29. Garcia A Senis YA , Antrobus R et al. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics 2006;6:5332–43.

30.

30. Maguire PB Wynne KJ , Harney DF , O'Donoghue NM , Stephens G , Fitzgerald DJ. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics 2002;2:642–8.

31.

31. Coppinger JA Cagney G , Toomey S et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096–104.

32.

32. Cicardi M Zingale L , Zanichelli A , Pappalardo E , Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005;27:286–98.

33.

33. Hauert J Patston PA , Schapira M. C1 inhibitor cross-linking by tissue transglutaminase. J Biol Chem 2000;275:14558–62.

34.

34. Garcia BA Smalley DM , Cho H , Shabanowitz J , Ley K , Hunt FD. The platelet microparticle proteome. J Proteome Res 2005;4:1516–21.

35.

35. Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 2005;37:1162–7.

36.

36. Stratmann B Tschoepe D Pathobiology and cell interactions of platelets in diabetes. Diabetes Vasc Dis Res 2005;2:16–23, doi: 10.3132/dvdr. 2005.001.

37.

37. Jin M Opalek JM , Marsh CB , Wu MH. Proteome comparison of alveolar macrophages with monocytes reveals distinct protein characteristics. Am J Respir Cell Mol Biol 2004;31:322–9.

38.

38. Barderas MG Darde VM , Duran MC , Egido J , Vivanco F. Characterization of circulating human monocytes by proteomic analysis. Methods Mol Biol 2007;357:319–28.

39.

39. Rosengren AT Nyman TA , Lahesmaa R. Proteome profiling of interleukin-12 treated human T helper cells. Proteomics 2005;5:3137–41.

40.

40. Boussac M Garin J Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 2000;21:665–72.

41.

41. Lominadze G Powell DW , Luerman GC , Link AJ , Ward RA , McLeish RK. Proteomic analysis of human neutrophil granules. Mol Cell Proteomics 2005;4:1503–21.

42.

42. Sotgiu S Barone R , Zanda B et al. Chitotriosidase in patients with acute ischemic stroke. Eur Neurol 2005;54:149–53.

43.

43. Kuwabara K Pinsky DJ , Schmidt AM et al. Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. J Biol Chem 1995;270:8179–87.

44.

44. Ozdemir FN Akcay A , Bilgic A , Akgul A , Arat Z , Haberal M. Effects of smoking and blood eosinophil count on the development of arteriovenous fistulae thrombosis in hemodialysis patients. Transplant Proc 2005;37:2918–21.

45.

45. Rohrbach MS Wheatley CL , Slifman NR , Gleich JG. Activation of platelets by eosinophil granule proteins. J Exp Med 1990;172:1271–4.

46.

46. Samoszuk M Corwin M , Hazen LS. Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting. Am J Hematol 2003;73:18–25.

47.

47. Yoon SW Kim TY , Sung MH , Kim CJ , Poo H. Comparative proteomic analysis of peripheral blood eosinophils from healthy donors and atopic dermatitis patients with eosinophilia. Proteomics 2005;5:1987–95.

48.

48. Lyngholm JM Nielsen HV , Holm M , Schiotz PO , Johnsen HA. Calreticulin is an interleukin-3-sensitive calcium-binding protein in human basophil leukocytes. Allergy 2001;56:21–8.

49.

49. Kakhniashvili DG Bulla LA Jr , Goodman SR. The human erythrocyte proteome: analysis by ion trap mass spectrometry. Mol Cell Proteomics 2004;3:501–09.

50.

50. Brezniak DV Moon DG , Beaver JA , Fenton JW 2nd. Haemoglobin inhibition of fibrin polymerization and clotting. Blood Coagul Fibrinolysis 1994;5:139–43.

51.

51. Pearson JD. Endothelial cell function and thrombosis. Baillieres Clin Haematol 1994;7:441–52.

52.

52. Banfi C Brioschi M , Wait R et al. Proteome of endothelial cell-derived procoagulant microparticles. Proteomics 2005;5:4443–55.

53.

53. Michaux G Abbitt KB , Collinson LM , Haberichter SL , Norman KE , Cutler FD. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006;10:223–32.

54.

54. Al-Nedawi K , Szemraj J , Cierniewski CS. Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 2005;25:1744–9.